To combat multiple resistance mechanisms mediated through PI3K, apitolisib, a dual PI3K/mTOR inhibitor, was studied in AML cells undergoing treatment with concurrent BCL-2 inhibition. Here, MTOR is linked to acute myeloid leukemia.